Drugs / ENX-104
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07472361 | Feb → Mar 2026 | — | Engrail Therapeutics INC | Completed | No outcome recorded |
| Phase 1 | NCT07253272 | Feb → Sep 2025 | — | Engrail Therapeutics INC | Completed | No outcome recorded |
| Phase 1 | NCT07253324 | Feb → Nov 2025 | major depressive disorder | Engrail Therapeutics INC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-18 | Engrail Therapeutics INC | Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia engrail.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENX-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07472361 ↗ |
| Route | Oral | “Oral solution” NCT07253272 ↗ |